168 related articles for article (PubMed ID: 38345769)
1. RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.
Singh H; Sahgal P; Kapner K; Corsello SM; Gupta H; Gujrathi R; Li YY; Cherniack AD; El Alam R; Kerfoot J; Andrews E; Lee A; Nambiar C; Hannigan AM; Remland J; Brais L; Leahy ME; Rubinson DA; Schlechter BL; Meyerson M; Kuang Y; Paweletz CP; Lee JK; Quintanilha JCF; Aguirre AJ; Perez KJ; Huffman BM; Rossi H; Abrams TA; Kabraji S; Trusolino L; Bertotti A; Sicinska ET; Parikh AR; Wolpin BM; Schrock AB; Giannakis M; Ng K; Meyerhardt JA; Hornick JL; Sethi NS; Cleary JM
Clin Cancer Res; 2024 Apr; 30(8):1669-1684. PubMed ID: 38345769
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of
Owen DR; Wong HL; Bonakdar M; Jones M; Hughes CS; Morin GB; Jones SJM; Renouf DJ; Lim H; Laskin J; Marra M; Yip S; Schaeffer DF
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29438965
[No Abstract] [Full Text] [Related]
3. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
[TBL] [Abstract][Full Text] [Related]
4. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
Cenaj O; Ligon AH; Hornick JL; Sholl LM
Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
[TBL] [Abstract][Full Text] [Related]
6. RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer.
Schrock AB; Lee JK; Sandhu J; Madison R; Cho-Phan C; Snider JW; Castellanos E; Venstrom JM; Fakih M
Oncologist; 2021 Jun; 26(6):469-475. PubMed ID: 33465286
[TBL] [Abstract][Full Text] [Related]
7. Plasma HER2 (
Siravegna G; Sartore-Bianchi A; Nagy RJ; Raghav K; Odegaard JI; Lanman RB; Trusolino L; Marsoni S; Siena S; Bardelli A
Clin Cancer Res; 2019 May; 25(10):3046-3053. PubMed ID: 30808777
[TBL] [Abstract][Full Text] [Related]
8. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.
DiPeri TP; Evans KW; Raso MG; Zhao M; Rizvi YQ; Zheng X; Wang B; Kirby BP; Kong K; Kahle M; Yap TA; Dumbrava EE; Ajani JA; Fu S; Keyomarsi K; Meric-Bernstam F
Clin Cancer Res; 2023 Nov; 29(21):4385-4398. PubMed ID: 37279095
[TBL] [Abstract][Full Text] [Related]
9. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF.
Hechtman JF; Zehir A; Yaeger R; Wang L; Middha S; Zheng T; Hyman DM; Solit D; Arcila ME; Borsu L; Shia J; Vakiani E; Saltz L; Ladanyi M
Mol Cancer Res; 2016 Mar; 14(3):296-301. PubMed ID: 26660078
[TBL] [Abstract][Full Text] [Related]
10. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.
Belli V; Matrone N; Napolitano S; Migliardi G; Cottino F; Bertotti A; Trusolino L; Martinelli E; Morgillo F; Ciardiello D; De Falco V; Giunta EF; Bracale U; Ciardiello F; Troiani T
J Exp Clin Cancer Res; 2019 Jun; 38(1):236. PubMed ID: 31164152
[TBL] [Abstract][Full Text] [Related]
11. HER2-Positive Metastatic Colorectal Cancer.
Robinson HR; Messersmith WA; Lentz RW
Curr Treat Options Oncol; 2024 May; 25(5):585-604. PubMed ID: 38539034
[TBL] [Abstract][Full Text] [Related]
12. Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation.
Wang C; Fakih M
J Natl Compr Canc Netw; 2021 Jun; 19(6):670-674. PubMed ID: 34214965
[TBL] [Abstract][Full Text] [Related]
13. Association of
Hino K; Nishina T; Kajiwara T; Bando H; Nakamura M; Kadowaki S; Minashi K; Yuki S; Ohta T; Hara H; Mizukami T; Moriwaki T; Ohtsubo K; Komoda M; Mitani S; Nagashima F; Kato K; Yamada T; Hasegawa H; Yamazaki K; Yoshino T; Hyodo I
JCO Precis Oncol; 2022 Aug; 6():e2200135. PubMed ID: 35952320
[TBL] [Abstract][Full Text] [Related]
14. Real-world association of HER2/
Stein SM; Snider J; Ali SM; Miksad RA; Alexander BM; Castellanos E; Schrock AB; Madison R; Swaminathan A; Venstrom JM; McCusker M
Future Oncol; 2021 Nov; 17(31):4101-4114. PubMed ID: 34463133
[TBL] [Abstract][Full Text] [Related]
15. Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.
Lesurf R; Griffith OL; Griffith M; Hundal J; Trani L; Watson MA; Aft R; Ellis MJ; Ota D; Suman VJ; Meric-Bernstam F; Leitch AM; Boughey JC; Unzeitig G; Buzdar AU; Hunt KK; Mardis ER
Ann Oncol; 2017 May; 28(5):1070-1077. PubMed ID: 28453704
[TBL] [Abstract][Full Text] [Related]
16. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Meric-Bernstam F; Hurwitz H; Raghav KPS; McWilliams RR; Fakih M; VanderWalde A; Swanton C; Kurzrock R; Burris H; Sweeney C; Bose R; Spigel DR; Beattie MS; Blotner S; Stone A; Schulze K; Cuchelkar V; Hainsworth J
Lancet Oncol; 2019 Apr; 20(4):518-530. PubMed ID: 30857956
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Siena S; Di Bartolomeo M; Raghav K; Masuishi T; Loupakis F; Kawakami H; Yamaguchi K; Nishina T; Fakih M; Elez E; Rodriguez J; Ciardiello F; Komatsu Y; Esaki T; Chung K; Wainberg Z; Sartore-Bianchi A; Saxena K; Yamamoto E; Bako E; Okuda Y; Shahidi J; Grothey A; Yoshino T;
Lancet Oncol; 2021 Jun; 22(6):779-789. PubMed ID: 33961795
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer.
Fakih MG
Oncologist; 2018 Apr; 23(4):474-477. PubMed ID: 29330210
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
[TBL] [Abstract][Full Text] [Related]
20. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
